Side effects, dropouts from treatment and cost consequences

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 2, 1998, Pages

  Montgomery, Stuart A ^a   Kasper, Siegfried ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cost; Depression; Reuptake inhibitor; Selective serotonin; Side effects; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; DOSULEPIN; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ARTICLE; BODY BURDEN; CARDIOTOXICITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG TOLERABILITY; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SUICIDE; UNEMPLOYMENT;

EID: 0031970601     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199802002-00001     Document Type: Article

References (23)

1. Anderson IM, Tomenson BM (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310:1433-1438.
2. Angst J (1992). How recurrent and predictable is depressive illness? In: Long-term treatment of depression. Montgomery SA, Rouillon F (editors). Chichester: Wiley. pp. 1-14.
3. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG (1994). Long-term treatment of depression with nefazodone. Psychopharm Bull 30:165-169.
4. Boyer WF, Feighner J (1993). The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Health economics of depression. Jönsson B, Rosenbaum J (editors). Chichester: Wiley. pp. 65-75.
5. Freeling P, Rao BM, Paykel ES, Sireling LI, Burton RH (1985). Unrecognised depression in general practice. BMJ 290:1880-1883.
6. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER (1993). The economic burden of depression in 1990. J Clin Psychiatry 54:405-418.
7. Guze SB, Robins E (1970). Suicide and primary affective disorders. Br J Psychiatry 117:437-438.
8. Henry JA, Alexander CA, Sener EK (1995). Relative mortality from overdose of antidepressants. BMJ 310:221-224.
9. Johnson DAW (1986). Depression: treatment compliance in general practice. Acta Psychiatr Scand 63 (suppl 290):447-453.
10. Jönsson B, Bebbington PE (1994). What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 164:665-673.
11. Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell WS, et al. (1986). Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 43:458-466.
12. Kind P, Sorensen J (1993). The costs of depression. Int Clin Psychopharmacol 7:191-195.
13. Montgomery SA, Kasper S (1995). Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9 (suppl 4):33-40.
14. Montgomery SA, Bebbington PE, Cowen P, Deakin W, Freeling P, Hallstrom C, et al. (1993). Guidelines for treating depressive illness with antidepressants. J Psychopharmacol 7:19-23.
15. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
16. Montgomery SA, Brown RE, Clark M (1996). Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 168:768-771.
17. Pande AC, Sayler ME (1993). Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 8:267-270.
18. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A (1993). Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306:683-687.
19. Stewart A (1994). Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. Br J Med Econ 7:67-79.
20. Stoudemire A, Frank R, Hedemark N, et al. (1986). The economic burden of depression. Gen Hosp Psychiatry 8:387-394.
21. Walinder J, Carlsson P, Rutz W (1993). The economic impact of an educational programme on diagnosis and treatment of depression in Sweden. In: Health economics of depression. Jönsson B, Rosenbaum J (editors). Chichester: Wiley. pp. 97-110.
22. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. (1989). The functioning and well being of depressed patients: results from the medical outcomes study. JAMA 262: 914-919.
23. West R (1992) Depression. London: Office of Health Economics.